S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.23
+1.55
+9.29%
MYO · Myomo Inc.
NYSE MKT LLC - BOATS Real Time Price • USD
$1.27
-0.00
(-0.39%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.27
$1.25
$1.28
52-WEEK RANGE
$1.27
$0.60
$1.89
What's happening
- MYO is down 0.39% today, trading at $1.27. — Live quote
- Volume today (5,710) is well below its 3-month average of 604,380. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.12 actual vs. $-0.10 estimated (-18.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 1
Buy 7
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
MYO
+38.46%
vs S&P 500
+25.68%
1-YEAR RETURN
MYO
+12.50%
vs S&P 500
-2.06%
6-MONTH RETURN
MYO
+58.69%
3-MONTH RETURN
MYO
+34.76%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.12
Est. $-0.10
MISS -18.8%
2026-04-26 (Q1 2026)
$-0.05
Est. $-0.12
BEAT +56.6%
2026-01-26 (Q4 2025)
$-0.09
Est. $-0.09
BEAT +2.2%
2025-10-26 (Q3 2025)
$-0.09
Est. $-0.11
BEAT +17.5%
Valuation Measures & Ratios
Enterprise Value4$52.3M
Forward P/E5—
PEG Ratio6-0.07
Price / Sales (TTM1)1.19
Price / Book76.89
EV4 / Revenue1.21
EV4 / EBITDA—
Profit Margin-33.53%
Operating Margin-27.05%
Return on Equity (ROE8)-142.02%
Return on Assets (ROA9)-40.07%
Avg Volume (3M)604,380
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $46.7M | $28.6M | $36.7M | $90.7M | $208.1M |
| P/E | -3.05 | -1.93 | -2.88 | -8.91 | -22.17 |
| Price/Sales | 1.12 | 0.72 | 0.95 | 2.51 | 6.87 |
| Price/Book | 8.01 | 3.17 | 2.51 | 5.15 | 9.60 |
| EV/Revenue | 1.14 | 0.78 | 0.70 | 2.15 | 6.21 |
| ROE | -262.90% | -164.07% | -87.01% | -57.82% | -43.29% |
| ROA | -43.36% | -40.18% | -37.35% | -26.34% | -22.97% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,066,314
Change from Prior Settlement-10.94%
% of Float—
Days to Cover (Short Ratio)2.62
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 21.3% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +12.5%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -33.5%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MYO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.7M | $10.1M | $10.1M | $9.7M | $9.8M | $9.2M | $7.5M | $3.8M |
| Gross profit | $8.4M | $6.9M | $6.4M | $6.1M | $6.6M | $6.9M | $5.3M | $2.3M |
| Operating income | -$2.3M | -$3.2M | -$3.5M | -$4.6M | -$3.5M | -$957.6K | -$1.1M | -$3.9M |
| Net income | -$4.0M | -$3.0M | -$3.7M | -$4.6M | -$3.5M | -$966.4K | -$1.1M | -$3.8M |
| EPS (diluted) | $-0.09 | $-0.07 | $-0.09 | $-0.11 | $-0.08 | $-0.03 | $-0.03 | $-0.10 |
| EPS (basic) | $-0.09 | $-0.07 | $-0.09 | $-0.11 | $-0.08 | $-0.03 | $-0.03 | $-0.10 |
| Operating margin | -$19 | -$31 | -$35 | -$48 | -$36 | -$10 | -$15 | -$104 |
| Net margin | -$34 | -$30 | -$36 | -$48 | -$35 | -$10 | -$15 | -$102 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $35.3M | $36.8M | $38.6M | $34.1M | $38.7M | $40.9M | $42.2M | $16.3M |
| Total liabilities | $29.5M | $27.8M | $27.2M | $19.5M | $21.1M | $19.2M | $17.5M | $7.0M |
| Stockholders' equity | $5.8M | $9.0M | $11.4M | $14.6M | $17.6M | $21.7M | $24.7M | $9.3M |
| Total current assets | $24.5M | $25.7M | $27.6M | $22.9M | $28.0M | $31.1M | $32.8M | $14.7M |
| Total current liabilities | $10.6M | $9.4M | $8.3M | $9.2M | $11.8M | $11.7M | $10.2M | $7.0M |
| Cash & equivalents | $11.2M | $11.4M | $14.1M | $12.6M | $14.2M | $19.8M | $24.4M | $6.6M |
| Marketable securities (current) | $2.2M | $4.3M | $4.3M | $0 | $1.2M | $4.3M | $493.0K | $0 |
| Accounts receivable | $4.9M | $4.8M | $4.1M | $5.3M | $7.1M | $4.7M | $3.8M | $3.7M |
| Inventory | $3.2M | $3.5M | $3.1M | $3.6M | $4.1M | $3.4M | $3.2M | $3.4M |
| Property, plant & equipment | $2.0M | $2.2M | $2.2M | $3.7M | $2.9M | $1.8M | $1.3M | $561.3K |
| Other non-current assets | $19.2K | $21.4K | $21.4K | $168.3K | $286.7K | $257.1K | $164.4K | $205.4K |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | $447.0K | $2.7M | $0 | $583.3K | $166.7K | — | $3.0M | — |
| Long-term debt | $11.5M | $10.9M | $11.2M | $2.4M | $1.3M | — | $11.2M | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $4.0K | $3.9K | $3.8K | $3.8K | $3.8K | $3.4K | $3.4K | $3.0K |
| Retained earnings | -$125.7M | -$121.7M | -$118.7M | -$114.9M | -$111.2M | -$106.6M | -$103.1M | -$102.9M |
| Accumulated other comprehensive income (loss) | $225.0K | $174.9K | $164.5K | $137.7K | $48.3K | -$116.5K | -$14.4K | $395.7K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.9M | -$2.2M | -$1.1M | -$1.8M | -$8.9M | -$2.7M | $3.4M | -$1.5M |
| Investing cash flow | $2.0M | -$494.3K | -$4.6M | $189.7K | -$757.3K | -$1.9M | -$1.4M | $2.8M |
| Financing cash flow | -$243.7K | $0 | $7.5M | -$50.0K | $4.0M | -$36.5K | $15.8M | -$199.5K |
| Free cash flow | -$2.0M | -$2.5M | $98.1K | -$3.9M | -$9.1M | -$3.3M | $2.5M | -$1.8M |
| Capital expenditures | $32.4K | $327.8K | -$1.2M | $2.1M | $221.5K | $670.7K | $860.2K | $320.7K |
| Share-based compensation | $1.0M | $597.2K | $565.0K | $584.0K | $394.9K | $540.2K | $321.9K | $324.2K |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | $374.1K | $691.0K | -$1.5M | -$1.9M | $2.3M | $637.1K | $443.3K | $1.0M |
| Change in inventory | -$622.3K | $447.3K | -$356.2K | -$185.9K | $654.0K | $550.8K | -$178.2K | $757.1K |
| Tax withholding on stock comp | $243.7K | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $40.9M | $32.6M | $19.2M | $15.6M | $13.9M |
| Gross profit | $26.9M | $23.2M | $13.2M | $10.3M | $10.3M |
| Operating income | -$14.4M | -$6.2M | -$8.2M | -$10.7M | -$10.3M |
| Net income | -$15.6M | -$6.2M | -$8.1M | -$10.7M | -$10.4M |
| EPS (diluted) | $-0.37 | $-0.16 | $-0.28 | $-1.52 | $-1.89 |
| EPS (basic) | $-0.37 | $-0.16 | $-0.28 | $-1.52 | $-1.89 |
| Operating margin | -$35 | -$19 | -$43 | -$69 | -$74 |
| Net margin | -$38 | -$19 | -$42 | -$69 | -$75 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $38.6M | $42.2M | $14.6M | $10.2M | $20.1M |
| Total liabilities | $27.2M | $17.5M | $5.6M | $3.8M | $4.7M |
| Stockholders' equity | $11.4M | $24.7M | $9.0M | $6.4M | $15.4M |
| Total current assets | $27.6M | $32.8M | $13.7M | $9.2M | $19.1M |
| Total current liabilities | $8.3M | $10.2M | $5.5M | $3.6M | $4.3M |
| Cash & equivalents | $14.1M | $24.4M | $6.9M | $5.3M | $15.5M |
| Marketable securities (current) | $4.3M | $493.0K | $2.0M | $0 | — |
| Accounts receivable | $4.1M | $3.8M | $2.4M | $1.9M | $2.0M |
| Inventory | $3.1M | $3.2M | $1.8M | $1.4M | $808.3K |
| Property, plant & equipment | $2.2M | $1.3M | $175.8K | $194.3K | $275.3K |
| Other non-current assets | $21.4K | $164.4K | $91.2K | $111.0K | $95.3K |
| Accrued liabilities | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | $3.0M | $3.0M | — | — | — |
| Long-term debt | $11.2M | $0 | — | — | — |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $3.8K | $3.4K | $2.7K | $775 | $687 |
| Retained earnings | -$118.7M | -$103.1M | -$96.9M | -$88.8M | -$78.1M |
| Accumulated other comprehensive income (loss) | $164.5K | -$14.4K | $83.7K | $43.2K | -$60.7K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$14.5M | -$3.3M | -$6.2M | -$10.2M | -$9.5M |
| Investing cash flow | -$7.1M | $260.0K | -$2.0M | -$310.8K | -$326.5K |
| Financing cash flow | $11.4M | $20.9M | $9.7M | $376.9K | $13.2M |
| Free cash flow | -$16.3M | -$4.7M | -$6.3M | -$10.3M | -$9.9M |
| Capital expenditures | $1.7M | $1.4M | $145.8K | $111.8K | $326.5K |
| Share-based compensation | $2.1M | $874.4K | $1.1M | $1.2M | $1.1M |
| Deferred income taxes | $0 | $0 | — | — | — |
| Change in accounts receivable | -$377.0K | $1.6M | $495.6K | -$47.4K | $1.0M |
| Change in inventory | $662.7K | $1.4M | $384.8K | $607.4K | $118.2K |
| Tax withholding on stock comp | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MYO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-06-08 to 2026-10-13
Recent transactions
- Insiders have net sold 47,738 shares over the last 182 days, across 0 purchases and 3 sales.
- Most recent: Kovelman Harry (Chief Medical Officer) — Grant / award of 32,500 shares on 2026-10-13.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)47,738 sh(3 txns)
Net Shares-47,738
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Kovelman Harry | Chief Medical Officer | Grant / award | 2026-10-13 | 32,500 |
| HENRY DAVID A | Chief Financial Officer | Grant / award | 2026-10-13 | 51,250 |
| GUDONIS PAUL R | Chief Executive Officer | Grant / award | 2026-10-13 | 71,250 |
| McClure Mary-Katherine Hale | Chief Commericial Officer | Grant / award | 2026-10-12 | 275,000 |
| Morris Milton Mayo | Reporting person | Open market sale | 2026-09-02 | 15,000 |
| Mitchell Micah | Chief Commercial Officer | Grant / award | 2026-08-07 | 58,409 |
| Manko Joseph M. Jr. | Director | Grant / award | 2026-06-25 | 78,704 |
| Crowley Thomas Aloysius Jr. | Reporting person | Grant / award | 2026-06-25 | 78,704 |
| KIRK THOMAS F | Reporting person | Grant / award | 2026-06-25 | 78,704 |
| Getz Heather C | Reporting person | Grant / award | 2026-06-25 | 78,704 |
| FEBBO WILLIAM J | Reporting person | Grant / award | 2026-06-25 | 78,704 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-13 | Kovelman Harry | Chief Medical Officer | Grant / award | 32,500 | $0.00 |
| 2026-10-13 | HENRY DAVID A | Chief Financial Officer | Grant / award | 51,250 | $0.00 |
| 2026-10-13 | GUDONIS PAUL R | Chief Executive Officer | Grant / award | 71,250 | $0.00 |
| 2026-10-12 | HENRY DAVID A | Chief Financial Officer | Tax withholding | 3,133 | $1.37 |
| 2026-10-12 | McClure Mary-Katherine Hale | Chief Commericial Officer | Grant / award | 275,000 | $0.00 |
| 2026-10-09 | HENRY DAVID A | Chief Financial Officer | Grant / award | 6,272 | $0.00 |
| 2026-10-09 | GUDONIS PAUL R | Chief Executive Officer | Grant / award | 8,363 | $0.00 |
| 2026-09-11 | Kovelman Harry | Chief Medical Officer | Open market sale | 15,488 | $1.27 |
| 2026-09-02 | Morris Milton Mayo | Reporting person | Open market sale | 15,000 | $1.41 |
| 2026-08-20 | Kovelman Harry | Chief Medical Officer | Open market sale | 17,250 | $1.73 |
| 2026-08-07 | Kovelman Harry | Chief Medical Officer | Grant / award | 55,149 | $0.00 |
| 2026-08-07 | Kovelman Harry | Chief Medical Officer | Tax withholding | 22,457 | $1.42 |
| 2026-08-07 | Mitchell Micah | Chief Commercial Officer | Grant / award | 58,409 | $0.00 |
| 2026-08-07 | Mitchell Micah | Chief Commercial Officer | Tax withholding | 21,559 | $1.42 |
| 2026-08-07 | GUDONIS PAUL R | Chief Executive Officer | Grant / award | 146,909 | $0.00 |
| 2026-08-07 | HENRY DAVID A | Chief Financial Officer | Grant / award | 68,644 | $0.00 |
| 2026-08-07 | HENRY DAVID A | Chief Financial Officer | Tax withholding | 25,310 | $1.42 |
| 2026-07-13 | HENRY DAVID A | Chief Financial Officer | Tax withholding | 5,166 | $1.09 |
| 2026-07-10 | HENRY DAVID A | Chief Financial Officer | Grant / award | 7,840 | $0.00 |
| 2026-07-10 | GUDONIS PAUL R | Chief Executive Officer | Grant / award | 10,454 | $0.00 |
| 2026-06-25 | Manko Joseph M. Jr. | Director | Grant / award | 78,704 | $0.00 |
| 2026-06-25 | Crowley Thomas Aloysius Jr. | Reporting person | Grant / award | 78,704 | $0.00 |
| 2026-06-25 | KIRK THOMAS F | Reporting person | Grant / award | 78,704 | $0.00 |
| 2026-06-25 | Getz Heather C | Reporting person | Grant / award | 78,704 | $0.00 |
| 2026-06-25 | FEBBO WILLIAM J | Reporting person | Grant / award | 78,704 | $0.00 |
| 2026-06-25 | Morris Milton Mayo | Reporting person | Grant / award | 78,704 | $0.00 |
| 2026-06-12 | Kovelman Harry | Chief Medical Officer | Tax withholding | 10,442 | $1.20 |
| 2026-06-12 | Mitchell Micah | Chief Commercial Officer | Tax withholding | 9,061 | $1.20 |
| 2026-06-12 | HENRY DAVID A | Chief Financial Officer | Tax withholding | 10,969 | $0.00 |
| 2026-06-08 | Mitchell Micah | Chief Commercial Officer | Tax withholding | 6,529 | $1.33 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:48 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 4 | 2026-10-13 | View on SEC.gov → |
| 2026-10-15 | 4 | 2026-10-13 | View on SEC.gov → |
| 2026-10-15 | 4 | 2026-10-13 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-11 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-08-21 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
Recent news
Headlines about MYO (Myomo Inc.). Links open the publisher — we don’t host full articles.
-
Myomo, Inc. (MYO) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-16 -
Myomo CMO Harry Kovelman sells $20,136 in company stock
Investing.com · 2026-10-16 -
Form 4 Myomo Inc: Harry Kovelman (Chief Medical Officer) For: 11 September
Investing.com UK · 2026-10-16 -
Form 4 Myomo Inc: David A. Henry (CFO) For: 13 October
Investing.com India · 2026-10-16 -
Myomo CEO Paul R. Gudonis Awarded 71,250 RSUs on October 13, 2026
Kalkine Media · 2026-10-15 -
Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer
Yahoo Finance · 2026-10-12 -
Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance · 2026-09-01 -
Myomo Q2 Earnings Call Highlights
Yahoo Finance · 2026-08-09
No headlines in this category right now — try “All”.